Biotech Values

[biotech_researcher]

Ariad- This interview with Olivier Pilley, GM of Ariad Pharmaceuticals- France, may mark the end of Marty Duvall reign as Ariad's Chief Commercial Officer and Exec. VP as he may have lost control of the troups:

Pilley:

Most recently, we signed a licensing deal with Otsuka. It is remarkable that we were able to command milestone payments from a Big Pharma company, which is indicative of Otsuka’s interest in and commitment to Iclusig®. It is a vote of confidence in us.

Remarkable?

Pilley:

There are three main features of ARIAD I would like to highlight. Firstly, as our model demonstrates, we are very focused on academic rigor and the quality of our scientific research. Haematology is intrinsically one of the most academic areas in medicine and pharmaceuticals, and we are expressly dedicated to the pursuit of quality academic results. This guarantees the effectiveness of our therapies.

Never heard that before..!



http://pharmaboardroom.com/interviews/interview-olivier-pilley-general-manager-ariad-pharmaceuticals-france/